• Home
  • Daewoong Pharmaceutical Co.,Ltd

Daewoong Pharmaceutical Co.,Ltd

About Daewoong Pharmaceutical Co.,Ltd

Since its establishment in 1945, Daewoong Pharmaceutical has grown to become one of the top 5 pharmaceutical companies in Korea. With its strong and competent in-house R&D and qualified manufacturing facilities (cGMP), Daewoong provides a total healthcare solution to patients across the globe. We manufacture various products (ETC&OTC) including Biologic, Chemical, Medical Device, etc. 

Products: Finished Dosage Formulations (Biologic & Chemical), APIs, Antibiotics, Enzymes
Interests: In-licencing, Out-l...

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • KR
  • 2015
    On CPHI since
  • 1000 - 4999
    Employees
Company types
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
View company profile
Contact info
Show contact info Hide contact info
Meet us at

CPHI Milan 2024

Fiera Milano, Italy
08 Oct 2024 - 10 Oct 2024
View Exhibitor Profile

Products from Daewoong Pharmaceutical Co.,Ltd (5)

  • NABOTA®

    Product NABOTA®

    Botulinum toxin type A  
    Indication: Glabella Lines (Approved in KR, US, CA, EU), Post Stroke Upper Limb Spasticity, Crow's feet, Blepharospasm, Benign Masseteric Hypertrophy (Approved in KR)
    - Nabota is the only 900kDa Neurotoxin approved in the US and EU since Botox.- It has demonstra...
  • CREZET

    Product CREZET

    1) Indication :  Treatment of primary hypercholesterolemia or to decrease elevated fat level in blood (mixed hyperlipidemia) in adult patients 
    2) Composition : Ezetimibe, Rosuvastain calcium (strength: 10/20mg, 10/10mg,10/5mg)
    3) Dosage & Administration : Once a day with or without m...
  • ENVLO®

    Product ENVLO®

    Envlo (Enavogliflozin) is a best-in-class SGLT2 inhibitor for T2DM. 
    Highlights of Envlo are: 
    * Launched in Korea from May 2023
    * Approved by Korea MFDS in 2022 for T2DM 
    * T2DM Phase III was completed in Korea as a monotherapy and in combinations with other anti-diabetics (du...
  • Eposis

    Product Eposis

    2000, 3000, 4000, 5000, 6000, 8000, 10000IU / Pre-filled syringe Inj.

    rhEPO (recombinant human erythropoietin)

    Indication:
    Anemia in chronic renal failure

    - EposisTM demonstrated significant improvement and safety for patients with anemia in Chronic Renal Failure (CRF).
    ...
  • FEXUCLUE®

    Product FEXUCLUE®

    Fexuclue (Fexuprazan) is the best-in-class novel anti acid secretion agent with rapid onset time and potent acid suppressive effect, addressing the growing unmet needs of PPIs

    Highlights of Fexuclue are: * Launched in Korea (2022) and Philippines (2023)
    * Approved in Chile and Ecuador qq...

Daewoong Pharmaceutical Co.,Ltd Resources (1)

  • DAEWOONG PR VIDEO (EN)

    Video DAEWOONG PR VIDEO (EN)

    We continue to take the initiative by making bold challenges and investments in R&D to leap forward as a global healthcare group. Following the 2022 launch of Fexuclue, a drug treating gastroesophageal reflux disease, the company released Envlo, a Type 2 diabetes treatment. By bolstering its R&D pipeline, Daewoong Pharmaceutical is developing first-in-class and best-in-class drugs.
    2023-07-27